Skip to main content
In stock|Targeted Therapy (Investigational)

Tunlametinib

Oncology TypeSolid Tumour
Drug Class / MechanismDNA Damage Response Inhibitor
No Image
Description

Tunlametinib is classified as a DNA Damage Response Inhibitor, sourced for use within our Targeted Therapy (Investigational) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic CategoryTargeted Therapy (Investigational)
Oncology TypeSolid Tumour

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3